Clinical Roundup Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL December 13, 2024Vol.50 No.46
Clinical Roundup Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial December 13, 2024Vol.50 No.46
Clinical Roundup Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma December 13, 2024Vol.50 No.46
Clinical Roundup Carvykti demonstrates higher rates of MRD negativity, phase III study shows December 13, 2024Vol.50 No.46
Clinical Roundup Genetic mutations accumulate in smokers with MDS, study shows December 13, 2024Vol.50 No.46
Clinical Roundup High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows December 13, 2024Vol.50 No.46
Clinical Roundup Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer December 13, 2024Vol.50 No.46
